Influence of chemotherapy to hormonal levels in postmenopausal breast cancer patients

Neoplasma

Volumn 55, Issue 4, 2008, Pages 294-298

  Pribylova, O ^a   Springer, D ^b   Svobodnik, A ^b   Kyr, M ^b   Zima, T ^b   Petruzelka, L ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

^b MASARYK UNIVERSITY   (Czech Republic)

Author keywords

Breast cancer; Chemotherapy; Hormonal levels; IGF 1; IGFBP 3; Postmenopausal

Indexed keywords

CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTRADIOL; FLUOROURACIL; FOLLITROPIN; HORMONE RECEPTOR; LUTEINIZING HORMONE; PROGESTERONE; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C; ANTINEOPLASTIC AGENT; ESTROGEN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER STAGING; CONTROLLED STUDY; DRUG EFFECT; ESTRADIOL BLOOD LEVEL; ESTROGEN SYNTHESIS; FEMALE; FOLLITROPIN BLOOD LEVEL; HORMONE BLOOD LEVEL; HUMAN; LUTEINIZING HORMONE BLOOD LEVEL; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; POSTMENOPAUSE; PROGESTERONE BLOOD LEVEL; ADJUVANT CHEMOTHERAPY; BREAST TUMOR; METABOLISM; MIDDLE AGED; PAGET NIPPLE DISEASE;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CHEMOTHERAPY, ADJUVANT; ESTRADIOL; ESTROGENS; FEMALE; FOLLICLE STIMULATING HORMONE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; LUTEINIZING HORMONE; MIDDLE AGED; POSTMENOPAUSE; PROGESTERONE;

EID: 49949112017     PISSN: 00282685     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. th edition, Lippincott Williams § Wilkins, Philadelphia, 2005;1399-1471.
2. POWELS TJ. Prognostic impact of amenorrhoea after adjuvant chemotherapy. European Journal of Cancer 1998; 34: 603-605.
3. Early Breast cancer Collaborative Group Ovarian ablation in early breast cancer: overview of randomised trails. Lancet 2000; 348: 1189-1196.
4. nd edition, Lippincott Williams § Wilkins, Philadelphia, 2000: 489-513.
5. SACHDEV D, YEE D. The IGF system and breast cancer, Endocrine Related Cancer 2001; 8: 197-209.
6. CULLEN KJ, YEE D, SLY WS et al. Insulin like growth factor receptor expression and function in human breast cancer. Cancer Research 1990; 50: 48-53. (Pubitemid 20029992)
7. CHO H, ARONICA SM, KATZENELLENBOGEN BS. Regulation of progesterone receptor gene expression in MCF-7 breast cancer cells. Endocrinology 1994; 134: 658-664
8. LEE AV, YEE D. Insuline-like growth factors and breast cancer. Biomedicine and Pharmacotherapy 1995; 49: 415-421.
9. Shapiro CL, Recht A. Side effects of adjuvant treatment of breast cancer. A Engl J Med 2001; 34: 1997. (Pubitemid 32568155)
10. GEISLER J, KING N, DOWSETT M et al. Influence of anastrozol, a non steroidal aromatase inhibitor, on in vivo aromatisation and plasma estrogen levels in postmenopausal women with breast cancer. Br. J. Cancer 1996; 74: 1286-1291.
11. LABAN C, BUSTIN SA, JENKINS PJ. The GH-IGF-1 axis and breast cancer. Trends Endocrinol. Meta. 2003; 14: 28-34.
12. GIOVANUCCI E. Insulin like growth factor-I and binding protein-3 and risk of cancer. Horm. Res. 1999; 51: Suppl 3, 34-41.
13. POLLAK M. IGF-I physiology and breast cancer. Recent Results Cancer Res. 1998, 152: 63-70.
14. ELLIS MJ, JENKINS S, HANFELT J et al. Insulin-like growth factors in human breast cancer. Breast Cancer Res. Treat. 1998; 52: 175-184.
15. MOSCHOS SJ, MANTZOROS CS. The role of IGF system in cancer: from basic to clinical studies and clinical applications. Oncology 2002; 63: 317-332. (Pubitemid 36151524)
16. FURSTENBERGER G, MORANT R, SENN HJ. Insulinelike growth factors and breast cancer. Onkologie 2003; 26: 290-294. (Pubitemid 36831220)
17. KAJDANIUK D, MAREK B. Influence of adjuvant chemotherapy with cyclophosphamide, methotrexate and 5-fluorouracil on plasma insulin-like growth factor-I and chosen hormones in breast cancer in pre-menopausal patients. Journal of Clinical Pharmacy § Therapeutics 2000; 25: 67-70.
18. KUTLUK O, OZGUR O. Measuring the impact of chemotherapy on fertility in women with breast cancer. Journal of clinical oncology 2006, 24: 4044-4046. (Pubitemid 46630768)
19. PEYRAT JP, REVILLION F, BONNETERRE J. Plasma insuline- like growth factor in primary breast cancer patients treated with adjuvant chemotherapy. British Journal of Cancer 1998; 77: 1669-1671.
20. BARNI S, LISSONI P, BIVIO F. serum levels of insulinelike growth factor-I in operable breast cancer in relation to main prognostic variables and their perioperative changes in relation to those of prolactin. Tumori 1994; 80: 212-215.
21. BRUNING PF, VAN DOORN J, BONFRER JM. Insulinlike growth-factor-binding protein 3 is decreased in early-stage operable pre-menopausal breast cancer. International Journal of Cancer 1995; 62: 266-270.
22. FAVONI RE, CUPIS A, PERROTTA A. Insulin-like growth factor-I and IGF-binding proteins blood serum levels in women with early- and late-stage breast cancer: mutual relationship and possible correlation with patientś hormonal status. Journal of Cancer Research and Clinical Oncology 1995; 121: 674-682.
23. DUNN SE, HARDMAN RA, KARI FW et al. Insuline-like growth factor-I alters drug sensitivity of HBL 100 human breast cancer cells by inhibition of apoptosis induced by diverse anticancer drugs. Cancer Research 1997; 57: 2687-2693.
24. HELLE SI, LONNING PE. Insulin-like growth factors in breast cancer. Oncologica 1996; 35: 19-22. (Pubitemid 27076979)
25. YASUMURA T, AKAMI T, MITSUO M et al. The effect of adjuvant therapy with or without tamoxifen on the endocrine function of patients with breast cancer. Jpn. J. Surg 1990; 20: 369-375.
26. ANJUM S, KHAN S, BAIG et al. Effect of chemotherapy on circulating steroid hormone levels in postoperative premenopausal breast cancer patients. J. Pak. Med. Assoc. 1991; 41: 296-298.
27. POIKONEN P, SAARTO T, ELOMAA I et al. Prognostic effect of amenorrhoea and elevated serum gonadotropin levels induced by adjuvant chemotherapy in premenopausal node-positive breast cancer patients. Eur. J. Cancer 2000; 36: 43-48.
28. JORDAN VC, FRITZ NF, LANGAN-FAHEY S et al. Alteration of endocrine parameters in premenopausal women with breast cancer during long-term adjuvant therapy with tamoxifen as the single agent. J. Natl. Cancer Inst. 1991; 16: 1488-1491.
29. STURGEON SR, POTISCHMAN N, MALONE KE et al. Serum levels of sex hormones and breast cancer risk in premenopausal women. Cancer Causes Control 2004; 15: 45-53.